quemliclustat + zimberelimab + platinum-based doublet

This therapy is a **combination regimen** under investigation primarily for the treatment of advanced or metastatic pancreatic ductal adenocarcinoma. It includes: - **Quemliclustat** (also known as AB680): a potent, selective, small molecule inhibitor of CD73, which suppresses extracellular adenosine production in the tumor microenvironment. Adenosine is immunosuppressive and high CD73 expression is associated with poor prognosis in multiple tumors. Inhibition of CD73 is intended to restore antitumor immune activity[3][7]. - **Zimberelimab**: a human monoclonal antibody targeting programmed cell death protein 1 (PD-1/Pdcd1), acting as a checkpoint inhibitor to activate immune responses against tumor cells[3][5]. - **Platinum-based doublet chemotherapy**: refers to a regimen combining two cytotoxic drugs, one being a platinum compound (typically cisplatin, carboplatin, or oxaliplatin), and the other a third-generation chemotherapeutic (frequently gemcitabine, paclitaxel, nab-paclitaxel, or others). These doublets form the standard backbone of many systemic anticancer therapies[2][4][5]. This combination is being studied as a first-line regimen in patients with advanced pancreatic cancer to determine whether the immunotherapeutic agents can improve efficacy when added to the platinum-based chemotherapy doublet[5].